Welcome to our dedicated page for Novo-Nordisk A/S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novo Nordisk A/S filings document the Danish healthcare company's financial reporting, product portfolio, pipeline progress and capital structure as a foreign private issuer. Form 6-K reports include operating and financial results, commercial updates for diabetes and obesity medicines, regulatory and clinical disclosures for products such as Wegovy, and development updates in areas including sickle cell disease.
The filing record also covers B-share repurchase programs, treasury-share ownership, share-capital information, governance matters and risk-related disclosures. These reports connect Novo Nordisk's chronic-disease business, GLP-1 franchise, biopharmaceutical research and shareholder-capital actions to formal regulatory disclosure.
Novo Nordisk A/S reports progress on its 2026 share repurchase programme. As part of a broader plan to buy back up to DKK 15 billion of B shares over 12 months from 4 February 2026, the company has been actively repurchasing shares in early March.
As of 6 March 2026, Novo Nordisk has repurchased 5,334,992 B shares at an average price of DKK 276.06, for a total of DKK 1,472,797,094. Following these transactions, it holds 22,724,791 B shares as treasury shares, equal to 0.5% of its total 4,465,000,000 A and B shares.
Novo Nordisk A/S reports that its employees have completed the election of new employee representatives to the company’s Board of Directors. These representatives are elected for a four-year term and, under Danish law, employee-elected members may make up half of the shareholder-elected board members.
The newly elected employee representatives will join the Board after the annual general meeting on 26 March 2026, when current employee board members Liselotte Hyveled and Tanja Villumsen, who did not run for re-election, will step down. Employee-elected directors have the same rights and responsibilities as shareholder-elected directors.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company is running an overall buyback of up to DKK 15 billion over 12 months beginning 4 February 2026, aimed at repurchasing B shares.
Under the specific programme running from 4 February 2026 to 4 May 2026, Novo Nordisk plans to buy back up to DKK 3.8 billion of B shares. As of 27 February 2026, it has repurchased 4,045,000 B shares at an average price of DKK 286.95, for a total of DKK 1,160,693,639.
Following these transactions, Novo Nordisk holds 21,434,799 B shares as treasury shares, representing 0.5% of its share capital. The company’s total share capital consists of 4,465,000,000 A and B shares, including treasury shares.
Novo Nordisk A/S is executing a share repurchase programme as part of an overall plan to buy back up to DKK 15 billion of B shares over a 12‑month period starting 4 February 2026. A specific tranche targets up to DKK 3.8 billion of B shares from 4 February to 4 May 2026.
From 4 February to 20 February 2026, the company repurchased 2,750,000 B shares at an average price of DKK 306.18, for a total of DKK 841,997,435. After these transactions, Novo Nordisk holds 20,139,799 B shares of DKK 0.10 as treasury shares, equal to 0.5% of its 4,465,000,000 total A and B shares.
Novo Nordisk reported headline phase 3 results from the REDEFINE 4 obesity trial comparing once-weekly CagriSema 2.4 mg/2.4 mg with tirzepatide 15 mg over 84 weeks in 809 people with obesity and comorbidities.
Using the efficacy estimand assuming full adherence, CagriSema led to 23.0% weight loss at 84 weeks versus 25.5% with tirzepatide. Under the treatment-regimen estimand, weight loss was 20.2% with CagriSema and 23.6% with tirzepatide. The primary endpoint of demonstrating non-inferiority of CagriSema to tirzepatide on weight loss was not achieved.
CagriSema showed a generally safe, well-tolerated profile with mostly mild to moderate gastrointestinal side effects that lessened over time. Novo Nordisk has submitted CagriSema for U.S. approval for weight management based on other pivotal trials, with an FDA decision anticipated by late 2026 and additional REDEFINE 11 and higher-dose CagriSema phase 3 readouts planned through 2027.
Novo Nordisk A/S has called its Annual General Meeting for 26 March 2026 at 14:00 (CET). The meeting will be held as a combined physical and virtual event, allowing shareholders to attend at Bella Center in Copenhagen or participate online by computer or mobile device.
Shareholders are encouraged to submit proxies or votes by correspondence in advance, with practical details provided in the accompanying meeting notice and via a live webcast. All shareholder-elected Board members are up for election, and the Board proposes re-electing Lars Rebien Sørensen as Chair, Cees de Jong as Vice Chair, and several other members, while nominating Helena Saxon, Jan van de Winkel and Ramona Sequeira as new Board members.
Novo Nordisk is updating investors on its ongoing share repurchase programme. The company plans to buy back B shares for up to DKK 15 billion over a 12‑month period starting 4 February 2026, including up to DKK 3.8 billion between 4 February and 4 May 2026.
As of 13 February 2026, Novo Nordisk has repurchased 1,750,000 B shares at an average price of DKK 305.03, for a total of DKK 533,796,640. The company now holds 19,139,799 B shares as treasury shares, equal to 0.4% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S reports insider transactions by its Chief Financial Officer, Karsten Munk Knudsen, in accordance with market abuse regulation. As Executive Vice President and CFO, he notified two sales of Novo Nordisk B shares.
On 10 February 2026, he sold 26,246 shares at a price of DKK 315.60 per share, for an aggregated amount of DKK 8,283,237.60, executed through JANE STREET NETHERLANDS B.V. He also sold 311 shares at DKK 315.70 per share, for an aggregated amount of DKK 98,182.70, on CBOE EUROPE - DXE PERIODIC (NL). These trades were reported as initial notifications under the rules for persons discharging managerial responsibilities and their closely associated persons.
Novo Nordisk A/S reports an insider share transaction by Executive Vice President for R&D and Chief Scientific Officer Martin Holst Lange. He sold 22,000 Novo Nordisk B shares at DKK 319.80 per share, for a total of DKK 7,035,600.
The transaction, carried out on 9 February 2026 on Nasdaq Copenhagen, was described as a sale of shares to cover tax on shares transferred under the company’s Long Term Incentive programme.
Novo Nordisk A/S is executing a large share repurchase programme of up to DKK 15 billion over 12 months beginning 4 February 2026. Within this, it plans to buy back B shares for up to DKK 3.8 billion from 4 February to 4 May 2026.
As of 6 February 2026, Novo Nordisk has repurchased 750,000 B shares at an average price of DKK 296.40, with a total value of DKK 222,297,903. Incentive plan activity led to a net transfer out of 3,841,954 B shares. The company now holds 18,283,326 B shares as treasury shares, equal to 0.4% of its 4,465,000,000 total A and B shares.